COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,196 Articles (22,713 medRxiv, 8,483 bioRxiv)

Most recent first Previous |  Page 1439: Articles 14381-14390  | Next

Gender Balance and Readability of COVID-19 Scientific Publishing: A Quantitative Analysis of 90,000 Preprint Manuscripts
Celi, L. A., Charpignon, M.-L., Ebner, D. K., Kaufman, A. R., McCoy, L. G., Millado, M. C., Park, J., Salciccioli, J., Situ, J.
10.1101/2021.06.14.21258917 — Posted: 2021-06-18
Working in a care home during the COVID-19 pandemic: How has the pandemic changed working practices?
Hanna, K. L., Giebel, C., Cannon, J., Shenton, J., Mason, S., Tetlow, H., Marlow, P., Rajagopal, M., Gabbay, M.
10.1101/2021.06.10.21258611 — Posted: 2021-06-18
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
O'Brien, M. P., Forleo Neto, E., Musser, B. J., Isa, F., Chan, K.-C., Sarkar, N., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., Hurt, C. B., Burwen, D. R., Marovich, M. A., Hou, P., Heirman, I., Davis, J. D., Turner, K. C., Ramesh, D., Mahmood, A., Hooper, A. T., Hamilton, J. D., Kim, Y., Purcell, L. A., Baum, A., Kyratsous, C. A., Krainson, J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A. T., Stahl, N., Lipsch, L., Braunstein, N., Herman, G., Yancopoulos, G. D., Weinreich, D. M., the Covid-19 Phase 3 Prevention Trial Team
10.1101/2021.06.14.21258567 — Posted: 2021-06-17
Effectiveness and Safety of Niclosamaide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management: Randomized controlled clinical trial
Abdulamir, A. S., Gorial, F. I., Saaedi, S. J., Maulood, M. F., Hashim, H. A., abdulrrazaq, M. K.
10.1101/2021.06.10.21258709 — Posted: 2021-06-17
Quantitative Analysis of Genomic Sequences of Virus RNAs Using a Metric-Based Algorithm
Belinsky, A., Kouzaev, G.
10.1101/2021.06.17.448868 — Posted: 2021-06-17
Molnupiravir, an Oral Antiviral Treatment for COVID-19
Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R. S., Mollan, K. R., Wolfe, C. R., Duke, E. R., Azizad, M. M., BorrotoiEsoda, K., Wohl, D. A., Loftis, A. J., Alabanza, P., Lipansky, F., Painter, W. P.
10.1101/2021.06.17.21258639 — Posted: 2021-06-17 Discussion: Onsite
SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
Saito, A., Nasser, H., Uriu, K., Kosugi, Y., Irie, T., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J., Ozono, S., Tokunaga, K., Butlertanaka, E. P., Tanaka, Y. L., Shimizu, R., Shimizu, K., Fukuhara, T., Kawabata, R., Sakaguchi, T., Yoshida, I., Asakura, H., Nagashima, M., Yoshimura, K., Kazuma, Y., Nomura, R., Horisawa, Y., Takaori-Kondo, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Nakagawa, S., Ikeda, T., Sato, K.
10.1101/2021.06.17.448820 — Posted: 2021-06-17
Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals.
Sokal, A., Barba-Spaeth, G., Fernandez, I., Broketa, M., Azzaoui, I., de La Selle, A., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., Bouvier-Alias, M., Crickx, E., Languille, L., Michel, M., Godeau, B., Gallien, S., Melica, G., Nguyen, Y., Zarrouk, V., Canoui-Poitrine, F., Noizat-Pirenne, F., Megret, J., Pawlotsky, J.-M., Fillatreau, S., Brunhs, P., Rey, F. A., Weill, J.-C., Reynaud, C.-A., Chappert, P., Mahevas, M.
10.1101/2021.06.17.448459 — Posted: 2021-06-17
Post-Infection Entry Mechanism of Ricin A Chain-Pokeweed Antiviral Proteins (RTA-PAPs) Chimeras is Mediated by Viroporins
Hassan, Y.
10.1101/2021.06.17.448882 — Posted: 2021-06-17
Western diet increases COVID-19 disease severity in the Syrian hamster
Port, J. R., Adney, D. R., Schwarz, B., Schulz, J., Sturdevant, D. E., Smith, B. J., Avanzato, V., Holbrook, M. G., Purushotham, J., Stromberg, K. A., Leighton, I., Bosio, C., Shaia, C., Munster, V.
10.1101/2021.06.17.448814 — Posted: 2021-06-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).